A detailed history of Capula Management LTD transactions in Abb Vie Inc. stock. As of the latest transaction made, Capula Management LTD holds 367 shares of ABBV stock, worth $61,024. This represents 0.0% of its overall portfolio holdings.

Number of Shares
367
Previous 183 100.55%
Holding current value
$61,024
Previous $31,000 132.26%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$163.84 - $199.33 $30,146 - $36,676
184 Added 100.55%
367 $72,000
Q2 2024

Aug 05, 2024

SELL
$154.79 - $180.76 $145,193 - $169,552
-938 Reduced 83.68%
183 $31,000
Q1 2024

May 09, 2024

BUY
$159.82 - $182.1 $179,158 - $204,134
1,121 New
1,121 $204,000
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $4.23 Million - $5.26 Million
31,906 Added 1879.03%
33,604 $4.53 Million
Q1 2023

May 10, 2023

BUY
$144.61 - $166.54 $245,547 - $282,784
1,698 New
1,698 $270,000
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $5.96 Million - $6.83 Million
44,397 New
44,397 $5.96 Million
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $3.8 Million - $4.8 Million
-35,336 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $2.78 Million - $3.16 Million
26,173 Added 285.64%
35,336 $3.77 Million
Q2 2021

Aug 13, 2021

BUY
$105.21 - $117.21 $777,186 - $865,830
7,387 Added 415.93%
9,163 $1.02 Million
Q1 2021

May 14, 2021

SELL
$102.3 - $112.62 $9.26 Million - $10.2 Million
-90,481 Reduced 98.07%
1,776 $192,000
Q1 2020

May 15, 2020

BUY
$64.5 - $97.79 $1.82 Million - $2.77 Million
28,280 Added 44.2%
92,257 $7.03 Million
Q4 2019

Feb 14, 2020

BUY
$72.13 - $90.25 $3.49 Million - $4.36 Million
48,327 Added 308.8%
63,977 $5.67 Million
Q2 2019

Aug 09, 2019

BUY
$65.7 - $83.98 $1.03 Million - $1.31 Million
15,650 New
15,650 $1.14 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $294B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Capula Management LTD Portfolio

Follow Capula Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capula Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Capula Management LTD with notifications on news.